Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.54 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | THRA | P10827 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15729561 | 0.91 | MAPT (0.57) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL24057021 | 0.89 | HPGD (0.49) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL26927452 | 0.89 | KDM1A (0.51) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL30443256 | 0.86 | KDM1A (0.52) | KDM1AMAOBTHRBGAAMAPT | |
| SCHEMBL30765211 | 0.86 | KDM1A (0.46) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL23112086 | 0.86 | KDM1A (0.46) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL24057016 | 0.86 | KDM1A (0.52) | KDM1AMAOBTHRBGAAMAPT | |
| SCHEMBL23599543 | 0.85 | GLRA1 (0.52) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL4055189 | 0.85 | GAA (0.51) | KDM1AMAOBTHRATHRBGAA | |
| SCHEMBL12137871 | 0.85 | KDM1A (0.45) | KDM1AMAOBTHRATHRBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574334-B | Novel phenolic compound and preparation method and application thereof | 江汉大学 | 2023-02-10 | — | — | CN | claimed |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4526300-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-6737125-B2 | SUCH AS 8,9-DIFLUORO-7-(4-PENTYLPHENYL)-2-PROPYL-2,3-DIHYDRO-1H -CYCLOPENTA(A)NAPHTHALENE; FOR USE IN AUTOMOBILE INTERIORS | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-05-18 | — | — | US | disclosed |
| US-20030108684-A1 | Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors | CLARIANT INTERNATIONAL LTD. | 2003-06-12 | — | — | US | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0142328-B1 | FLUOROPHENOXY COMPOUNDS, HERBICIDAL COMPOSITIONS AND METHODS | THE DOW CHEMICAL COMPANY (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4888050-A | GRASS CONTROL | THE DOW CHEMICAL COMPANY (US) | 1989-12-19 | — | — | US | disclosed |
| US-4750931-A | GRASSY WEEDS | THE DOW CHEMICAL COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0142328-A2 | Fluorophenoxy compounds, herbicidal compositions and methods | THE DOW CHEMICAL COMPANY (US) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108684-A1 | Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors | SCO2, CYP2F1, OGFOD1 | KDM1A 3106/4885MAOB 1635/4885THRA 3556/4885 |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | KDM1A 2001/4885MAOB 4464/4885THRA 3433/4885 |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | KDM1A 3306/4885MAOB 525/4885THRA 2569/4885 |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | KDM1A 1781/4885MAOB 4435/4885THRA 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.